FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
DIMETANE-TEN
brompheniramine maleate
LOE Approaching
Thayer Medical
INJECTION · INJECTABLE
nasal congestion due to the common coldhay fever+3
1958
NDA30/100
DIOVAN
valsartan
LOE Approaching
Novartis
ORAL · CAPSULE
hypertensionto lower blood pressure+8
1996
SMNDA30/100
DIOVAN
valsartan
LOE Approaching
Novartis
ORAL · TABLET
hypertensionto lower blood pressure in adults+3
2001
SMNDA30/100
DIOVAN HCT
valsartan and hydrochlorothiazide
LOE Approaching
Novartis
ORAL · TABLET
hypertensionto lower blood pressure+8
1998
NDA30/100
DIPENTUM
olsalazine sodium
LOE Approaching
Viatris (2)
ORAL · CAPSULE
ulcerative colitis
1990
NDA30/100
DIPRIVAN
propofol
LOE Approaching
Fresenius Kabi
INJECTION · INJECTABLE
1989
NDA30/100
DIPROLENE
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · CREAM, AUGMENTED
1986
NDA30/100
DIPROLENE
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · LOTION, AUGMENTED
1988
NDA30/100
DIPROLENE
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · OINTMENT, AUGMENTED
1983
NDA30/100
DIPROLENE AF
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · CREAM, AUGMENTED
1987
NDA30/100
DIPROSONE
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · LOTION
1977
NDA30/100
DIPROSONE
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · OINTMENT
1976
NDA30/100
DIPROSONE
betamethasone dipropionate
LOE Approaching
Merck & Co.
TOPICAL · CREAM
1975
NDA30/100
DISIPAL
orphenadrine hydrochloride
LOE Approaching
ORAL · TABLET
1957
NDA30/100
DISOPHROL
dexbrompheniramine maleate; pseudoephedrine sulfate
LOE Approaching
Merck & Co.
ORAL · TABLET, EXTENDED RELEASE
nasal congestion due to the common coldhay fever+6
1963
NDA30/100
DITROPAN
oxybutynin chloride
LOE Approaching
Johnson & Johnson
ORAL · TABLET
overactive bladder with symptoms of urge urinary incontinenceurgency+3
1975
NDA30/100
DITROPAN
oxybutynin chloride
LOE Approaching
Johnson & Johnson
ORAL · SYRUP
overactive bladder with symptoms of urge urinary incontinenceurgency+3
1979
NDA30/100
DITROPAN XL
oxybutynin chloride
LOE Approaching
Johnson & Johnson
ORAL · TABLET, EXTENDED RELEASE
overactive bladder with symptoms of urge urinary incontinenceurgency+3
1998
NDA30/100
DIULO
metolazone
LOE Approaching
Pfizer
ORAL · TABLET
saltwater retention including: edema accompanying congestive heart failure+8
1981
NDA30/100
DIUPRES-250
chlorothiazide; reserpine
LOE Approaching
Merck & Co.
ORAL · TABLET
pregnancyjust+3
1958
NDA30/100
DIUPRES-500
chlorothiazide; reserpine
LOE Approaching
Merck & Co.
ORAL · TABLET
pregnancyjust+3
1958
NDA30/100
DIURIL
chlorothiazide
LOE Approaching
ORAL · TABLET
the management of hypertension eitherto enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension+6
1958
NDA30/100
DIURIL
chlorothiazide
LOE Approaching
Bausch Health
ORAL · SUSPENSION
the management of hypertension eitherto enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension+6
1961
NDA30/100
DIVIGEL
estradiol
LOE Approaching
Convert Pharmaceuticals
TRANSDERMAL · GEL
2007
NDA30/100